67 reports

  • GENETIC DISORDERS, COMMON SYMPTOMS OF GENETIC DISORDERS
  • GENETIC DISORDERS, PROGRESSION OF CF

Global Genetic Disorders Drugs Market to 2023 - A Rapidly Growing Treatment Landscape Driven by Targeted Complement System Inhibitors and Enzyme Replacement Therapies to Treat PNH and Lysosomal Storage Disease Summary Genetic disorders are caused by abnormalities in a person’s genome and represent...

  • Genetic Disorder
  • World
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.

Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials Executive Summary Chapter ## – Introduction Chapter ## – Trends in Genetic Disorders dealmaking ##. ##.

  • Genetic Disorder
  • Pathology
  • World
  • Demand

Ten-year test volume and reagent sales forecasts for the following categories: & nbsp; & nbsp; & nbsp; - & nbsp; Infectious Diseases Genetic Diseases & nbsp; & nbsp; & nbsp; - & nbsp; Cancer & nbsp; & nbsp; & nbsp; - & nbsp; Paternity Testing/

  • Genetic Disorder
  • Molecular Diagnostic
  • Spain
  • Demand
  • Forecast
  • JAPAN - CYSTIC FIBROSIS THERAPEUTICS MARKET (MILLION US$), 2014 - 2016
  • 6.2 CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET & FORECAST

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period. Cystic fibrosis is among the most common life-threatening genetic disorders worldwide. It is caused by defects in a single gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR. The increasing...

  • Genetic Disorder
  • World
  • Market Size
  • AbbVie Inc.
  • Editas Medicine, Inc.
  • GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022
  • 5 Cystic Fibrosis Market, By Treatment Method

Cystic fibrosis is a genetic disease.

  • Genetic Disorder
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • 5 Cystic Fibrosis Market, By Treatment Method
  • GLOBAL CYSTIC FIBROSIS MARKET, BY TREATMENT METHOD, 2015 & 2022

Cystic fibrosis is a genetic disease.

  • Genetic Disorder
  • AbbVie Inc.
  • Allergan plc
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • Carrier Screening Market: Revenue in USD million, by Disease Type, Global, 2018-2023
  • 4. KEY INFERENCES

The global carrier screening market is expected to account for a value of USD 2,237 million, registering a CAGR of about 9.8% during the forecast period (2018-2023). Carrier screening is one of the genetic tests that provide the data on whether a particular person carries a gene for certain genetic disorders or not. When the test is performed...

  • Genetic Disorder
  • 23andMe, Inc.
  • Cepheid
  • Illumina, Inc.
  • Sequenom, Inc.
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders
  • Proportion of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) to Genetic Disorders

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Global Clinical Trials Review, H2, 2015" provides an overview of Adrenoleukodystrophy (Adrenomyeloneuropathy/...

  • Genetic Disorder
  • World
  • Aldagen, Inc.
  • Asklepion Pharmaceuticals, LLC
  • Nutra Pharma Corporation
  • Clinical Trials by G7 Countries: Proportion of Primary Immune Deficiency (PID) to Genetic Disorders Clinical Trials
  • Clinical Trials by E7 Countries: Proportion of Primary Immune Deficiency (PID) to Genetic Disorders Clinical Trials

Primary Immune Deficiency (PID) Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Primary Immune Deficiency (PID) Global Clinical Trials Review, H2, 2015" provides an overview of Primary Immune Deficiency (PID) clinical trials scenario. This report provides top line data relating to the...

  • Genetic Disorder
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited

GENETIC FACTORS ARE ALSO A CONTRIBUTOR TO IPF; AROUND ## IN ## PEOPLE WITH IPF HAVE ANOTHER FAMILY MEMBER WITH THE DISEASE DUE TO A DISEASE CALLED FAMILIAL IDIOPATHIC FIBROSIS.

  • Genetic Disorder
  • World
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • PULMONARY HYPERTENSION

Engages in the development of drugs in areas such as immuno-oncology, oncology, immunoscience, virology, cardiovascular, fibrotic diseases, and metabolic and genetically defined diseases.

  • Genetic Disorder
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • II. Etiology and Genetics of Cystic Fibrosis
  • 1. CYSTIC FIBROSIS: DISEASE OVERVIEW

Cystic fibrosis is a rare genetic disorder caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7. It largely affects the lungs and digestive system, and causes the secretions to become thick and sticky. The individuals with cystic fibrosis develop lung disease, resulting...

  • Cystic Fibrosis
  • Genetic Disorder
  • World
  • AbbVie Inc.
  • Vertex Pharmaceuticals Incorporated

(USA) ##.

  • Genetic Disorder
  • Pharmaceutical
  • China
  • World
  • Market Shares
  • Snapshot of Cystic Fibrosis
  • 06. Introduction

About Cystic Fibrosis Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited disease. The primary symptoms of cystic fibrosis include high salt content in the sweat, breathing difficulties, secretion of abnormally viscous mucus, respiratory complications, difficulties related to digestion, and growth anomalies. Cystic...

  • Genetic Disorder
  • Europe
  • Actavis plc
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • INTRODUCTION

IT IS AN AUTOSOMAL RECESSIVE GENETIC disorder caused by mutations in the CF gene.

  • Genetic Disorder
  • North America
  • United States
  • AstraZeneca PLC
  • Novartis AG

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Canada
  • France
  • Italy
  • Forecast

Cystic fibrosis and bone disease: are we missing a genetic link?

  • Genetic Disorder
  • Forest Laboratories, Inc.
  • Novartis AG
  • Pharmaxis Ltd
  • Vertex Pharmaceuticals Incorporated
  • PREVALENCE OF GENETIC DISORDERS (2012)
  • 8.2 GENETIC DISORDERS

The molecular cytogenetics market is projected to reach USD 2.52 billion by 2021 from USD 1.55 billion in 2016, at a CAGR of 10.1% from 2016 to 2021. The global molecular cytogenetics market is segmented based on product, technique, application, end user, and region. The kits and reagents segment is expected to register the highest growth...

  • Cytogenetic
  • Genetic Disorder
  • United States
  • Market Size
  • Agilent Technologies, Inc.
  • PROPORTION OF DOWN SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF DOWN SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*

Down Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Down Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Down Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Down Syndrome. Report includes...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • F. Hoffmann-La Roche Ltd.
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF FABRY DISEASE TO GENETIC DISORDERS CLINICAL TRIALS
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF FABRY DISEASE TO GENETIC DISORDERS CLINICAL TRIALS

Fabry Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Fabry Disease Global Clinical Trials Review, H2, 2017" provides an overview of Fabry Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Fabry Disease. Report includes...

  • Clinical Trial
  • Drug Discovery And Development
  • Genetic Disorder
  • World
  • Product Initiative
  • PROPORTION OF GAUCHER DISEASE TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF GAUCHER DISEASE TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*

Gaucher Disease Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Gaucher Disease Global Clinical Trials Review, H2, 2017" provides an overview of Gaucher Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Gaucher Disease. Report...

  • Biopharmaceutical
  • Genetic Disorder
  • Pathology
  • World
  • Product Initiative
  • PROPORTION OF FRAGILE X SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF FRAGILE X SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*

Fragile X Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Fragile X Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Fragile X Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Fragile X Syndrome....

  • Genetic Disorder
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF MUCKLE-WELLS SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF MUCKLE-WELLS SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS

Muckle-Wells Syndrome Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Muckle-Wells Syndrome Global Clinical Trials Review, H2, 2017" provides an overview of Muckle-Wells Syndrome clinical trials scenario. This report provides top line data relating to the clinical...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Novartis AG
  • PROPORTION OF LYSOSOMAL STORAGE DISORDER TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • CLINICAL TRIALS BY E7 COUNTRIES: PROPORTION OF LYSOSOMAL STORAGE DISORDER TO GENETIC DISORDERS CLINICAL TRIALS

Lysosomal Storage Disorder Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Lysosomal Storage Disorder Global Clinical Trials Review, H2, 2017" provides an overview of Lysosomal Storage Disorder clinical trials scenario. This report provides top line data relating...

  • Clinical Trial
  • Genetic Disorder
  • Neurological Disorder
  • Therapy
  • World
  • PROPORTION OF DUCHENNE MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF DUCHENNE MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*

Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017" provides an overview of Duchenne Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical...

  • Clinical Trial
  • Genetic Disorder
  • Neurological Disorder
  • World
  • Product Initiative
  • PROPORTION OF BECKER MUSCULAR DYSTROPHY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • Clinical Trials by G7 Countries: Proportion of Becker Muscular Dystrophy to Genetic Disorders Clinical Trials

Becker Muscular Dystrophy Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Becker Muscular Dystrophy Global Clinical Trials Review, H1, 2017" provides an overview of Becker Muscular Dystrophy clinical trials scenario. This report provides top line data relating to the clinical trials...

  • Genetic Disorder
  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • PROPORTION OF ALPHA- ANTITRYPSIN DEFICIENCY TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*

Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Alpha- Antitrypsin Deficiency Global Clinical Trials Review, H1, 2017" provides an overview of Alpha- Antitrypsin Deficiency clinical trials scenario. This report provides top line data relating to the...

  • Genetic Disorder
  • Therapy
  • World
  • Product Initiative
  • Grifols, S.A.
  • PROPORTION OF ALPHA-MANNOSIDOSIS TO GENETIC DISORDERS CLINICAL TRIALS, E7 COUNTRIES (%), 2017*
  • Clinical Trials by G7 Countries: Proportion of Alpha-Mannosidosis to Genetic Disorders Clinical Trials

Alpha-Mannosidosis Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Alpha-Mannosidosis Global Clinical Trials Review, H1, 2017" provides an overview of Alpha-Mannosidosis clinical trials scenario. This report provides top line data relating to the clinical trials on Alpha-Mannosidosis....

  • Genetic Disorder
  • Neurological Disorder
  • Therapy
  • World
  • Product Initiative
  • PROPORTION OF CHEDIAK-HIGASHI SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS, G7 COUNTRIES (%), 2017*
  • CLINICAL TRIALS BY G7 COUNTRIES: PROPORTION OF CHEDIAK-HIGASHI SYNDROME TO GENETIC DISORDERS CLINICAL TRIALS

Chediak-Higashi Syndrome Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Chediak-Higashi Syndrome Global Clinical Trials Review, H1, 2017" provides an overview of Chediak-Higashi Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials...

  • Blood Disease
  • Genetic Disorder
  • World
  • Product Initiative
  • Miltenyi Biotec GmbH
  • Proportion of Polycystic Kidney Disease to Genetic Disorders Clinical Trials, G7 Countries (%), 2016*
  • Proportion of Polycystic Kidney Disease to Genetic Disorders Clinical Trials, E7 Countries (%), 2016*

Polycystic Kidney Disease Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Polycystic Kidney Disease Global Clinical Trials Review, H2, 2016" provides an overview of Polycystic Kidney Disease clinical trials scenario. This report provides top line data relating to the clinical trials...

  • Clinical Trial
  • Drug Discovery And Development
  • Genetic Disorder
  • World
  • Product Initiative